Arsenic trioxide inhibits cell proliferation and human papillomavirus oncogene expression in cervical cancer cells

Area of Science:

• Oncology
• Molecular Biology
• Virology

Background:

• Arsenic trioxide (As2O3) exhibits anticancer properties, but its mechanisms in solid tumors, especially cervical cancer, require further elucidation.
• Previous studies indicated As2O3 induces apoptosis and inhibits human papillomavirus (HPV) oncogenes in cervical cells.

Purpose of the Study:

• To investigate the effects of As2O3 on various human cervical cancer cell lines.
• To explore the underlying molecular mechanisms of As2O3's anticancer activity in cervical cancer.

Main Methods:

• Cell viability was assessed using MTT assays across five human cervical cancer cell lines (HPV-positive and HPV-negative).
• Expression levels of HPV E6, E7, p53, Rb, and transcription factor AP-1 were analyzed at mRNA and protein levels.
• Enzyme-linked immunosorbent assay (ELISA) was used to measure AP-1 protein expression.

Main Results:

• HPV-negative C33A cells were more sensitive to As2O3 than HPV-positive cells.
• HPV 18-positive cell lines (HeLa, C4-I) showed greater sensitivity to As2O3 compared to HPV 16-positive lines (CaSki, SiHa).
• As2O3 treatment significantly decreased HPV E6 and E7 oncogene expression, while increasing p53 and Rb protein levels. AP-1 expression was also reduced.

Conclusions:

• As2O3 effectively inhibits the growth of cervical cancer cells through modulation of HPV oncogenes and tumor suppressor pathways.
• The differential sensitivity of cell lines suggests HPV status and type influence As2O3 efficacy.
• Arsenic trioxide represents a promising therapeutic agent for cervical cancer treatment.